Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Caroline Baumal Sells 2,816 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the sale, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $27.44 on Friday. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -13.52 and a beta of 0.94. The business’s fifty day simple moving average is $31.88 and its two-hundred day simple moving average is $33.82. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.17) EPS. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers grew its position in shares of Apellis Pharmaceuticals by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 123,565 shares of the company’s stock worth $4,740,000 after buying an additional 2,644 shares in the last quarter. Arizona State Retirement System grew its holdings in Apellis Pharmaceuticals by 12.7% during the 2nd quarter. Arizona State Retirement System now owns 22,013 shares of the company’s stock worth $844,000 after acquiring an additional 2,473 shares in the last quarter. Savant Capital LLC purchased a new position in Apellis Pharmaceuticals during the 2nd quarter valued at about $522,000. State of New Jersey Common Pension Fund D raised its holdings in shares of Apellis Pharmaceuticals by 6.6% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after purchasing an additional 2,820 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of Apellis Pharmaceuticals by 46.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 12,754 shares of the company’s stock worth $489,000 after purchasing an additional 4,060 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on APLS. Bank of America reduced their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. JPMorgan Chase & Co. cut their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Citigroup decreased their price target on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research note on Tuesday, December 17th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.94.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).